Why the study?
SGLT2 inhibitors have shifted from glucose-lowering drugs to organoprotective agents via pleiotropic mechanisms that require comprehensive mechanistic and clinical evaluation.
Do SGLT2 inhibitors provide cardiovascular protection in patients with heart failure, chronic kidney disease, and post-myocardial infarction?
Design
Review of scientific papers from PubMed and Google Scholar
Key result
SGLT2 inhibitors provide consistent mortality and morbidity benefits across the entire spectrum of left ventricular ejection fraction and chronic kidney disease, regardless of glycemic status.
Authors
Loading...
May support expanded SGLT2 inhibitor use across LVEF and CKD spectra; leaves open confirmation by large randomized trials.
Do SGLT2 inhibitors provide cardiovascular protection in patients with heart failure, chronic kidney disease, and post-myocardial infarction?
This review highlights the pleiotropic mechanisms and landmark clinical evidence establishing SGLT2 inhibitors as foundational therapy for cardiovascular and renal protection.
Sagan et al. (2026) conducted a review in Cardiovascular Disease, Heart Failure, and Chronic Kidney Disease. SGLT2 inhibitors was evaluated. SGLT2 inhibitors provide consistent mortality and morbidity benefits across the entire spectrum of left ventricular ejection fraction and chronic kidney disease, regardless of glycemic status.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: